[1] 中国残疾人康复协会脊髓损伤康复专业委员会,国际脊髓学会中国脊髓损伤学会,中华医学会泌尿外科学分会尿控学组. 脊髓损伤患者泌尿系管理与临床康复指南[J]. 中国康复理论与实践, 2013, 19(4): 301-317. [2] Bozkurt IH, Yalcinkaya F, Sertcelik MN, et al. A good alternative to indwelling catheter owing to benign prostate hyperplasia in elderly: memotherm prostatic stent [J]. Urology, 2013, 82(5): 1004-1007. [3] Chenoweth C, Saint S. Preventing catheter-associated urinary tract infections in the intensive care unit [J]. Crit Care Clin, 2013, 29(1): 19-32. [4] 张科技,刘晓艳,陈旭. 截瘫患者尿路感染常见病原菌检测及耐药性分析[J]. 中华医院感染学杂志, 2015, 25(2): 324-326. [5] 刘铸. 泌尿外科住院患者医院感染的诱因分析[J]. 中华医院感染学杂志, 2013, 23(4): 820-822. [6] 毛绒秋,张言圣,彭慧. 脊髓损伤康复期尿路感染的危险因素[J]. 中国康复医学杂志, 2015, 25(10): 957-962. [7] Fox CP, McMillan AK, Bishton MJ, et al. IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosfamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma [J]. Br J Haematol, 2008, 141(2): 244-248. [8] 卢守四,高钧. 脊髓损伤并发尿路感染的菌群分布及药物治疗[J]. 中国康复理论与实践, 2011, 17(8): 758-760. [9] 杨帆,封亚玲,张美霞. 间歇导尿对预防脊髓损伤患者泌尿系感染的研究[J]. 陕西医学杂志, 2011, 40(3): 379-380. [10] Gastmeier P, Schwab F, Sohr D, et al. Reproducibility of the surveillance effect to decrease nosocomial infection rates [J]. Infect Control Hosp Epidemiol, 2009, 30(10): 993-999. [11] 申正义,田德英. 医院感染学[M]. 北京:中国医药科技出版社, 2007: 989-1005. [12] Wise R. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy [J]. Clin Pharmacokinet, 1986, 11(6): 470-482. [13] 周炯,陈政,马小军. 多重耐药铜绿假单胞菌引起复发性尿路感染一例[J]. 中国医学科学院学报, 2012, 34(3): 310-312. [14] Dielubanza EJ, Mazur DJ, Schaeffer AJ. Management of non-catheter-associated complicated urinary tract infection [J]. Infect Dis Clin North Am, 2014, 28(1): 121-134. [15] Stein GE, Schooley SL, Nicolau DP. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli [J]. Int J Antimicrob Agents, 2008, 32(4): 320-325. [16] Chen YH, Ko WC, Hsueh PR. The role of fluoroquinolones in the management of urinary tract infections in areas with high rates of fluoroquinolone-resistant uropathogens [J]. Eur J Clin Microbiol Infect Dis, 2012, 31(8): 1699-1704. [17] 熊旭东. PK/PD 参数与抗菌药物的优化用药[J]. 抗感染药学, 2012, 9(1): 11-13. [18] 陈栋,刘智勇,陈亮. 2011年尿路感染病原菌分布及其耐药性分析[J]. 中华医院感染学杂志, 2012, 22(20): 4658-4660. [19] 霍红旭,蔡文清,杨敬芳,等. 导尿管伴随性尿路感染及其防治[J]. 临床泌尿外科杂志, 1998, 13(9): 283. [20] 郑波,唐伟,陈明,等. 尿路感染诊断与治疗中国专家共识(2015版)[J]. 中华泌尿外科杂志, 2015, 36(4): 241-244. [21] 马小军,徐英春,刘正印. ABX指南——感染性疾病的诊断与治疗[M]. 北京:科学技术文献出版社, 2012: 85-87. [22] 马雅萍,钱小毛. 经尿道膀胱肿瘤切除术后尿路感染的原因分析及预防对策[J]. 中华医院感染学杂志, 2013, 23(1): 80-82. [23] 徐敏,徐榕,张优琴,等. 留置导尿与医院泌尿系感染的关系[J]. 中华医院感染学杂志, 2010, 11(5): 368-369. [24] Heyns CF. Urinary tract infection associated with conditions causing urinary tract obstruction and stasis, excluding urolithiasis and neuropathic bladder [J]. World J Urol, 2012, 30(1): 77-83. [25] Meddings J, Rogers MAM, Krein SL, et al. Reducing unnecessary urinary catheter use and other strategies to prevent catheter-associated urinary tract infection: an integrative review [J]. BMJ Qual Saf, 2014, 23(4): 277-289. [26] 陈楠,陈晓农. 复杂性尿路感染的诊断与治疗[J]. 中华全科医师杂志, 2005, 4(9): 522-523. |